On August 27, 2020, Triumvira Immunologics Inc. successfully completed a US$55 million Series A financing round. The financing was co-led by Northpond Ventures, LLC and Leaps by Bayer, the impact investment unit of Bayer AG. Additional investors include Oceanpine Capital and Viva Biotech Holdings, and existing investors include Bloom Burton & Co. and the Centre for Commercialization of Cancer Immunotherapy (C3i).